# US 2024/0255493 A1 · Cancer screening in companion animals

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0255493 A1
- Document ID: US20240255493A1
- Status: Published application
- Kind: A1
- Application number: 18/585,626
- Filed: 2024-02-23
- Published: 2024-08-01
- Earliest claimed: 2021-08-24
- Assignees: Oncotect, Inc.
- Applicants: Oncotect, Inc.
- Inventors: Chan Namgong
- Web page: https://patentgrep.com/patent/US20240255493A1

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- G01N 33/5085: {of invertebrates}
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N 33/5751: of the skin, e.g. melanoma
- G16H 10/40: for data related to laboratory analysis, e.g. patient specimen analysis
- G16H 15/00: ICT specially adapted for medical reports, e.g. generation or transmission thereof
- G16H 30/20: for handling medical images, e.g. DICOM, HL7 or PACS
- G16H 30/40: for processing medical images, e.g. editing
- G16H 40/67: for remote operation
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G01N 2333/43534: from Caenorhabditis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

An economical and non-invasive method of using a behavioral response, a chemotaxis response, and/or a neuronal response of Caenorhabditis elegans (C. elegans) to screen for and/or detect cancer, such as screen for and/or detect early-stage cancer, in companion animals and humans is provided. Systems and kits using C. elegans to test and/or screen for and/or detect cancer, such as early-stage cancer, in companion animals and humans is also provided.

## Claims

### Claim 1

A method of screening for cancer in a subject, the method comprising:
detecting a behavioral response, a chemotaxis response, and/or a neuronal response of a nematode, or nematodes, to a biological sample obtained from the subject;
determining whether the behavioral response, chemotaxis response, and/or neuronal response of the nematode or nematodes exceeds or is within a threshold for a positive response, wherein a positive response to the sample indicates the subject has cancer or is at risk for having cancer; and
identifying the subject as having cancer or as being at risk for having cancer if the behavioral response, chemotaxis response, and/or neuronal response of the nematode or nematodes exceeds or is within a threshold for a positive response.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nematode, or nematodes, is a wild-type nematode, a mutant nematode or a transgenic nematode.

### Claim 3 (depends on 1)

The method of claim 1, wherein the nematode, or nematodes, is a wild-type recombinant, or transgenic Caenorhabditis elegans (C. elegans).

### Claim 4

(canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein a positive chemotaxis response comprises chemotaxis toward the biological sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein the biological sample is urine.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of hemangioma, lymphoma, osteosarcoma, plasma cell tumor, and mast cell tumor, transitional cell carcinoma and/or melanoma.

### Claim 8

A method for determining the effect of a treatment on the development of cancer in a subject, the method comprising:
detecting a behavioral response, a chemotaxis response, and/or a neuronal response of a nematode, or nematodes, to a biological sample obtained from the subject;
determining whether the behavioral response, chemotaxis response, and/or neuronal response exceeds or is within a threshold for a positive response, wherein a positive response to the sample indicates the treatment has not rendered the cancer undetectable; and
identifying the treatment of the subject as not having rendered the cancer undetectable if the behavioral response, chemotaxis response, and/or neuronal response exceeds or is within a threshold for a positive response.

### Claim 9 (depends on 8)

The method of claim 8, wherein a positive chemotaxis response comprises chemotaxis toward the biological sample.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject is a companion animal.

### Claim 11

A method of screening for and/or detecting cancer in a subject, the method comprising:
detecting a behavioral response, a chemotaxis response, and/or a neuronal response of a nematode, or nematodes, to (a) a biological sample obtained from a subject, and (b) at least one sample from the same or a different source, using a microfluidic approach to detect the behavioral response, the chemotaxis response, and/or the neuronal response;
determining the behavioral response, chemotaxis response, and/or the neuronal response of the nematode or nematodes, wherein if the behavioral response, chemotaxis response, and/or the neuronal response of the nematode or nematodes exceeds or is within a pre-determined response to the samples indicate the subject has cancer or is at risk for having cancer; and
identifying the subject as having cancer or as being at risk for having cancer if the behavioral response, chemotaxis response, and/or the neuronal response of the nematode or nematodes exceeds or is within the pre-determined threshold response to the samples.

### Claim 12 (depends on 11)

The method of claim 11, wherein the nematode is a wild-type nematode, a mutant nematode or a transgenic nematode.

### Claim 13 (depends on 11)

The method of claim 11, wherein the nematode, or nematodes, is C. elegans.

### Claim 14 (depends on 11)

The method of claim 11, wherein a positive chemotaxis response comprises chemotaxis toward the biological sample.

### Claim 15 (depends on 11)

The method of claim 11, wherein the biological sample is urine.

### Claim 16

(canceled)

### Claim 17

A kit for: (i) determining a presence of, and/or a risk of a presence of a cancer in a subject; or (ii) determining the effect of a treatment on development of cancer in a subject wherein the kit comprises:
(a) a receptable to contain a biological sample from the subject; and
(b) instructions providing guidance regarding the biological sample and steps to obtain results from a test to determine a behavioral response, a chemotaxis response, and/or a neuronal response of a nematode to the biological sample.

### Claim 18 (depends on 17)

The kit of claim 17, wherein the subject is a companion animal or a human subject:

### Claim 19

A computer-implemented method executed on a computer system, or computer readable medium operated thereon for: (i) determining a presence of, and/or a risk of a presence of a cancer in a subject; or (ii) determining an effect of a treatment on cancer development in subject, the method comprising:
a) monitoring a behavioral response, a chemotaxis response, and/or a neuronal response for a nematode, or a plurality of nematodes, to a biological sample;
b) determining whether the behavioral response, the chemotaxis response and/or the neuronal response exceeds or is within a threshold for a positive response; and
c) identifying whether there is a presence of and/or a risk for a presence of cancer in the subject,
wherein the presence of, and/or the risk of a presence of cancer in the subject is determined if the behavioral response, the chemotaxis response or the neuronal response exceeds or is within the threshold for a positive response.

### Claim 20 (depends on 19)

The computer-implemented method of claim 19, wherein determining if the behavioral response, the chemotaxis response or the neuronal response exceeds or is within a threshold for a positive response comprises evaluation of the behavioral response, the chemotaxis response or the neuronal response of the nematode or plurality of nematodes via artificial intelligence and/or machine learning to determine if the behavioral response, the chemotaxis response or the neuronal response exceeds or is within the threshold for a positive response.

### Claim 21

(canceled)
